Skip to content
The Nexus
DossierENTITY

Most-Favored-Nation

Coverage of Most-Favored-Nation in the Nexus archive.

Earliest in view: Apr 23 · 20:53 UTCMost recent: Apr 23 · 20:53 UTC
Co-mentioned in this coverage
Donald J. Trumpperson1Regeneron Pharmaceuticalsorganization1TrumpRxorganization1Medicaidtopic1Praluenttopic1U.S. Food and Drug Administration (FDA)organization1
Recent coverage
  • HEALTHApr 23 · 20:53 UTCAP NEWS
    Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative

    President Donald Trump announced a deal with Regeneron Pharmaceuticals to lower drug prices under the most-favored-nation initiative, including discounted Medicaid pricing and a $225 price for cholesterol drug Praluent on the TrumpRx website. The agreement, part of broader efforts to reduce healthcare costs ahead of midterms, also includes $27 billion in U.S. R&D investments and expedited FDA approval for Regeneron's gene therapy.